University of Calgary
UofC Navigation

Dr. Mark Giembycz


Mark Giembycz, Professor

University of Calgary, Cumming School of Medicine





Physiology & Pharmacology


Telephone number: 403.210.8562


Email address:


Primary Institute:   Snyder Institute for Chronic Diseases

Research  Interests:

The principal research focus of my laboratory is the elucidation of the mechanism of action of existing and novel anti-inflammatory therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma and allied respiratory conditions that are characterized by chronic inflammation. Specifically, these include phosphodiesterase (PDE) 4 inhibitors, inhaled corticosteroid (ICS)/long-acting 2-adrenoceptor agonist (LABA) combination therapies and novel targets such as activators of the nuclear hormone receptor, peroxisome proliferator-activated receptor  (PPAR). More recently, in collaboration with the Department of Chemistry (U of C), we have used crystallography-driven computational chemistry to identify, optimize and synthesize a novel series of PDE inhibitors based on a lead isoxazolopyridazinone derivative. These compounds may have unique anti-inflammatory activity and their study has formed a novel research activity that could provide new insights into better ways of treating airways inflammation.


Techniques used in Dr. Giembycz's laboratory:

Cell culture, ELISA, real-time RT-PCR, western blotting, promoter-luciferase constructs, receptor over-expression, electrophoretic mobility shift assays,  siRNA knockdown, in vitro and in vivo pharmacology, classical enzymology, radioligand binding.


Administrative assistant:

Tiziana (Tiz) Reiter
Phone number: 403.210.6766